Abstract:Abstract Background Thiopurine therapy is associated with an increased risk of serious adverse events in patients with Inflammatory Bowel Disease (IBD). Thiopurine S-methyltransferase (TPMT) is the enzyme responsible for metabolism, and its determination helps identify patients at risk of toxicity. This study aims to explore the level of correspondence between the TPMT genotype and enzymatic activity (phenotype) with the objective of preventing adverse events prior to the commencement of thiopurine therapy. Methods Consecutive patients with IBD, Crohn’s Disease (CD) or Ulcerative Colitis (UC), were included. Genotype was conducted for the most prevalent TPMT variants (TPMT*2, TPMT*3B, TPMT*3C), TPMT enzymatic activity assessment, and quantification of 6-thioguanine nucleotide (6-TGN) levels. Adverse effects were documented, along with the administration of biologics, mesalazine, ACE inhibitors or allopurinol. The primary objective was to evaluate the concordance between TPMT genotype and phenotype. Secondary objectives included determining the prevalence of genotype and phenotype within our patient cohort, 6-TGN serum levels, the prevalence of adverse events and identifying potential pharmacological inducers of the phenotype. Results A total of 218 patients were included (131 with CD and 81 with UC). Thirteen patients did not initiate thiopurines, and 34.63% (71/205) had discontinued treatment. The most observed adverse events were myelotoxicity (15.12%), gastrointestinal toxicity (12.20%), and hepatic toxicity (5.37%). TPMT activity exhibited a trimodal distribution, with 87.61% (191/218) having normal activity, 11.47% having intermediate activity, and 1% having low activity. Genotypically, 90.83% (198/218) had a wild-type genotype, 8.72% (18/218) had a heterozygous genotype, and 0.5% (1/218) had a homozygous genotype. The concordance index between phenotype and genotype was calculated at 0.57. Significantly, myelotoxicity was associated with the presence of genotypic variants (p=0.004). 6-TGN levels did not correlate with TPMT activity and concurrent medications did not affect TPMT activity . Conclusion The proactive assessment of TPMT (phenotype or genotype) before initiating thiopurine therapy effectively mitigates the occurrence of myelotoxicity in IBD patients. Importantly, the level of concordance between TPMT activity and genotype is moderate, with genotyping serving as the more reliable approach for preselecting patients susceptible to myelotoxic reactions.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: in patients with Inflammatory Bowel Disease (IBD), the consistency between Thiopurine S - methyltransferase (TPMT) genotype and enzyme activity (phenotype), in order to prevent the occurrence of serious adverse events before starting thiopurine treatment. Specifically, the use of thiopurine drugs (such as azathioprine and 6 - mercaptopurine) in IBD patients is associated with an increased risk of serious adverse reactions. TPMT is a key enzyme responsible for thiopurine metabolism, and its activity level can affect the efficacy and toxicity of the drug. Therefore, evaluating the consistency between TPMT genotype and enzyme activity can help identify patients who are more likely to be toxic to thiopurine drugs, thereby optimizing the treatment plan and reducing the occurrence of adverse reactions. ### Research Background Thiopurine drugs are widely used in IBD patients, but the risk of serious adverse events (such as bone marrow suppression, gastrointestinal toxicity, hepatotoxicity, etc.) associated with them is relatively high. The activity of the TPMT enzyme is encoded by the TPMT gene, and gene variation can affect the activity of the enzyme. Therefore, by detecting the TPMT genotype and enzyme activity, high - risk patients can be identified before treatment, thereby avoiding or reducing the occurrence of adverse reactions. ### Main Research Objectives 1. **Evaluate the consistency between TPMT genotype and enzyme activity**: This is the main objective of the study, aiming to determine whether the genotype can accurately predict enzyme activity. 2. **Determine the distribution of TPMT genotype and enzyme activity in the patient cohort**: including the frequencies of different genotypes and enzyme activity levels. 3. **Measure the level of 6 - thioguanine nucleotide (6 - TGN)**: 6 - TGN is an active metabolite of thiopurine drugs, and its level is related to the efficacy and toxicity of the drug. 4. **Record the incidence of adverse events**: especially bone marrow suppression, gastrointestinal toxicity, hepatotoxicity, etc. 5. **Identify drugs that may affect the TPMT phenotype**: For example, whether biologics, mesalazine, ACE inhibitors or allopurinol, etc. will affect the TPMT enzyme activity. ### Conclusion Studies have shown that evaluating TPMT genotype or enzyme activity before starting thiopurine treatment can effectively reduce the occurrence of adverse reactions such as bone marrow suppression. Although the consistency between TPMT genotype and enzyme activity is moderate (the consistency index is 0.57), genotyping is still a more reliable method for pre - screening patients who are prone to bone marrow suppression reactions. Through these research results, doctors can better select drugs and doses suitable for patients before treatment, thereby improving the safety and effectiveness of treatment.

P798 Study of the concordance between the enzymatic activity of Thiopurine S-methyltransferase and polymorphisms in the TPMT gene in patients with Inflammatory Bowel Disease

Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine.

Thiopurine Methyltransferase Gene Polymorphisms in Chinese Patients with Inflammatory Bowel Disease

Correlation between Thiopurine S-methyltransferase and Thiopurines Toxicity in Patients with Inflammatory Bowel Disease

Association Between Thiopurine S-Methyltransferase Polymorphisms And Thiopurine-Induced Adverse Drug Reactions In Patients With Inflammatory Bowel Disease: A Meta-Analysis

Thiopurine S-methyltransferase Polymorphisms and Thiopurine Toxicity in Treatment of Inflammatory Bowel Disease.

The Role of Pharmacogenetics in the Therapeutic Response to Thiopurines in the Treatment of Inflammatory Bowel Disease: A Systematic Review

Should Thiopurine Methyltransferase Genotypes and Phenotypes Be Measured Before Thiopurine Therapy in Patients with Inflammatory Bowel Disease?

Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT

Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn's disease patients

Evaluation of thiopurine methyltransferase genotyping and enzyme activity detection in treatment of patients with inflammatory bowel disease

Prospective Evaluation of Pharmacogenomics and Metabolite Measurements Upon Azathioprine Therapy in Inflammatory Bowel Disease

Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance

Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics

Significance of genetic polymorphism of the thiopurine S-methyltransferase for individualizing 6-mercaptopurine chemotherapy

Role of TPMT Genetic Polymorphism in the Individualized Treatment of Thiopurine Drug

Role of Thiopurine S-Methyltransferase Detection in the Treatment of Inflammatory Bowel Disease

Significance of TPMT activity and TGNs level detection for individualizing 6-mercaptopurine chemotherapy]

P909 Proactive therapeutic drug monitoring and pharmacogenomics in mercaptopurine therapy for ulcerative colitis

[Relationship Between Single Nucleotide Polymorphisms in Thiopurine Methyltransferase Gene and Tolerance to Thiopurines in Acute Leukemia].

Inosine Triphosphate Pyrophosphatase and NUDT15 Are Good Predictors of Clinical Outcomes in Thiopurine-Treated Chinese Patients with Inflammatory Bowel Disease.